CVRx (CVRX) Projected to Post Quarterly Earnings on Tuesday

CVRx (NASDAQ:CVRX) is projected to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $14.1560 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last released its earnings results on Monday, August 4th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.05). CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%.The company had revenue of $13.59 million during the quarter, compared to analysts’ expectations of $13.22 million. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

CVRX stock opened at $10.19 on Monday. CVRx has a one year low of $4.30 and a one year high of $18.55. The company’s fifty day moving average price is $8.51 and its 200-day moving average price is $7.44. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The company has a market capitalization of $266.49 million, a PE ratio of -4.85 and a beta of 1.26.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. William Blair raised shares of CVRx to a “strong-buy” rating in a report on Monday, July 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of CVRx in a report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 target price on shares of CVRx in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Investors Weigh In On CVRx

A number of hedge funds have recently bought and sold shares of CVRX. Balyasny Asset Management L.P. raised its holdings in CVRx by 65.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after buying an additional 267,063 shares during the period. Geode Capital Management LLC raised its holdings in CVRx by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company’s stock valued at $2,249,000 after buying an additional 23,079 shares during the period. Marshall Wace LLP raised its stake in shares of CVRx by 238.1% in the second quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after acquiring an additional 246,548 shares during the period. Bank of America Corp DE raised its stake in shares of CVRx by 7.6% in the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock valued at $524,000 after acquiring an additional 6,312 shares during the period. Finally, Cresset Asset Management LLC boosted its stake in shares of CVRx by 3.5% during the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after purchasing an additional 1,823 shares during the period. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.